Top

Published in:

01-06-2020 | Chronic Obstructive Lung Disease | Original Paper

Time-updated resting heart rate predicts mortality in patients with COPD

Authors: Albert J. Omlor, Franziska C. Trudzinski, Mohamad Alqudrah, Frederik Seiler, Frank Biertz, Claus F. Vogelmeier, Tobias Welte, Henrik Watz, Benjamin Waschki, Titus J. Brinker, Stefan Andreas, Sebastian Fähndrich, Peter Alter, Rudolf A. Jörres, Michael Böhm, Robert Bals, German COSYCONET Cohort

Published in: Clinical Research in Cardiology | Issue 6/2020

Abstract

High resting heart rate (RHR) is associated with higher mortality in the general population and in cardiovascular disease. Less is known about the association of RHR with outcome in chronic obstructive pulmonary disease (COPD). In particular, the time-updated RHR (most recent value before the event) appears informative. This is the first study to investigate the association of time-updated RHR with mortality in COPD. We compared the baseline and time-updated RHR related to survival in 2218 COPD patients of the German COSYCONET cohort (COPD and Systemic Consequences—Comorbidities Network). Patients with a baseline RHR > 72 beats per minute (bmp) had a significantly (p = 0.049) higher all-cause mortality risk (adjusted hazard ratio (HR) of 1.37 (1.00–1.87) compared to baseline RHR ≤ 72 bpm. The time-updated RHR > 72 bpm was markedly superior (HR 1.79, 1.30–2.46, p = 0.001). Both, increased baseline and time-updated RHR, were independently associated with low FEV1, low TLCO, a history of diabetes, and medication with short-acting beta agonists (SABAs). In conclusion, increased time-updated RHR is associated with higher mortality in COPD independent of other predictors and superior to baseline RHR. Increased RHR is linked to lung function, comorbidities and medication. Whether RHR is an effective treatment target in COPD, needs to be proven in controlled trials.

Agusti AG (2005) Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2(4):367–370CrossRefPubMed

Chen W, Thomas J, Sadatsafavi M, FitzGerald JM (2015) Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 3(8):631–639. https://doi.org/10.1016/S2213-2600(15)00241-6 CrossRefPubMed

Mannino DM, Thorn D, Swensen A, Holguin F (2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32(4):962–969. https://doi.org/10.1183/09031936.00012408 CrossRefPubMed

Cuthbert JJ, Kearsley JW, Kazmi S, Kallvikbakka-Bennett A, Weston J, Davis J, Rimmer S, Clark AL (2019) The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol 108(2):185–193. https://doi.org/10.1007/s00392-018-1342-z CrossRefPubMed

Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, van Veldhuisen DJ, Böhm M (2010) The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int J Cardiol 145(2):172–176. https://doi.org/10.1016/j.ijcard.2010.04.082 CrossRefPubMed

Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B (2012) Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186(2):155–161CrossRefPubMed

Tockman MS, Pearson JAYD, Fleg JL, Metter EJ, Kao SY, Pal KGRAM, Cruise LJ, Fozard JL (1995) Rapid decline in FEV 1 a new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 151:390–398CrossRefPubMed

Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: role of comorbidities. Eur Respir J 28(6):1245–1257. https://doi.org/10.1183/09031936.00133805 CrossRefPubMed

Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Böhm M (2014) Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 103(2):149–159. https://doi.org/10.1007/s00392-013-0644-4 CrossRefPubMed

10.

Munzel T, Hahad O, Gori T, Hollmann S, Arnold N, Prochaska JH, Schulz A, Beutel M, Pfeiffer N, Schmidtmann I, Lackner KJ, Keaney JF Jr, Wild PS (2019) Heart rate, mortality, and the relation with clinical and subclinical cardiovascular diseases: results from the Gutenberg Health Study. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01466-2 CrossRefPubMedPubMedCentral

11.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D (2019) Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clin Res Cardiol 108(7):806–814. https://doi.org/10.1007/s00392-018-1410-4 CrossRefPubMed

12.

Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894. https://doi.org/10.1016/S0140-6736(10)61259-7 CrossRefPubMed

13.

Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102(1):11–22. https://doi.org/10.1007/s00392-012-0467-8 CrossRefPubMed

14.

Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112(6):736–749CrossRefPubMed

15.

Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O’Donnell M, Yusuf S (2015) Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension 65(3):651–661. https://doi.org/10.1161/HYPERTENSIONAHA.114.04568 CrossRefPubMed

16.

Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlof B, Edelman JM, Devereux RB (2010) All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 31(18):2271–2279. https://doi.org/10.1093/eurheartj/ehq225 CrossRefPubMed

17.

Gillum RF, Makuc DM, Feldman JJ (1991) Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 121(1 Pt 1):172–177CrossRefPubMed

18.

Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, Jensen JS, Jensen GB (2013) Resting heart rate is a predictor of mortality in COPD. Eur Respir J 42(2):341–349. https://doi.org/10.1183/09031936.00072212 CrossRefPubMed

19.

Warnier MJ, Rutten FH, de Boer A, Hoes AW, De Bruin ML (2014) Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS ONE 9(8):e105152. https://doi.org/10.1371/journal.pone.0105152 CrossRefPubMedPubMedCentral

20.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD, Investigators S (2018) Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J 39(33):3128–3134. https://doi.org/10.1093/eurheartj/ehy451 CrossRefPubMedPubMedCentral

21.

Hamill V, Ford I, Fox K, Böhm M, Borer JS, Ferrari R, Komajda M, Steg PG, Tavazzi L, Tendera M, Swedberg K (2015) Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med 128(10):1102–1108. https://doi.org/10.1016/j.amjmed.2015.04.042e1106 CrossRefPubMed

22.

Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Glaser S, Holle R, Watz H, Korn S, Adaskina N, Biertz F, Vogel C, Vestbo J, Wouters EF, Rabe KF, Sohler S, Koch A, Jorres RA (2016) The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med 114:27–37. https://doi.org/10.1016/j.rmed.2016.03.008 CrossRefPubMed

23.

Fahndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jorres RA, Greulich T, Vogelmeier CF, Bals R (2017) Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res 18(1):171. https://doi.org/10.1186/s12931-017-0655-1 CrossRefPubMedPubMedCentral

24.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jorres RA (2018) The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med 134:79–85. https://doi.org/10.1016/j.rmed.2017.12.003 CrossRefPubMed

25.

Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350(10):1005–1012. https://doi.org/10.1056/NEJMoa021322 CrossRefPubMed

26.

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET (2005) Standardisation of spirometry. Eur Respir J 26(2):319–338. https://doi.org/10.1183/09031936.05.00034805 CrossRefPubMed

27.

Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J, Initiative ERSGLF (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324–1343. https://doi.org/10.1183/09031936.00080312 CrossRefPubMedPubMedCentral

28.

Vogel CU, Wolpert C, Wehling M (2004) How to measure heart rate? Eur J Clin Pharmacol 60(7):461–466. https://doi.org/10.1007/s00228-004-0795-3 CrossRefPubMed

29.

Leitao Filho FS, Alotaibi NM, Yamasaki K, Ngan DA, Sin DD (2018) The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Rev Respir Med 12(2):125–135. https://doi.org/10.1080/17476348.2018.1419869 CrossRefPubMed

30.

Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT (2016) Beta-blockers in COPD: time for reappraisal. Eur Respir J 48(3):880–888. https://doi.org/10.1183/13993003.01847-2015 CrossRefPubMed

31.

Sami R, Sadegh R, Esmailzadehha N, Mortazian S, Nazem M, Zohal M (2018) Association of anthropometric indexes with disease severity in male patients with chronic obstructive pulmonary disease in Qazvin, Iran. Am J Mens Health. https://doi.org/10.1177/1557988318760053 CrossRefPubMedPubMedCentral

32.

Ricci F, Wollmer P, Engstrom G, Fedorowski A, Hamrefors V (2018) Markers of cardiovascular autonomic dysfunction predict COPD in middle-aged subjects. Eur Respir J. https://doi.org/10.1183/13993003.02481-2017 CrossRefPubMed

33.

Anker SD, von Haehling S (2011) The obesity paradox in heart failure: accepting reality and making rational decisions. Clin Pharmacol Ther 90(1):188–190. https://doi.org/10.1038/clpt.2011.72 CrossRefPubMed

34.

Horwich TB, Fonarow GC, Clark AL (2018) Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 61(2):151–156. https://doi.org/10.1016/j.pcad.2018.05.005 CrossRefPubMed

35.

Alter P, Jorres RA, Watz H, Welte T, Glaser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF (2018) Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol 261:172–178. https://doi.org/10.1016/j.ijcard.2018.02.074 CrossRefPubMed

36.

Andreas S, Anker SD, Scanlon PD, Somers VK (2005) Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128(5):3618–3624. https://doi.org/10.1378/chest.128.5.3618 CrossRefPubMed

37.

Pan L, Dong W, Li H, Miller MR, Chen Y, Loh M, Wu S, Xu J, Yang X, Shima M, Deng F, Guo X (2018) Association patterns for size-fractioned indoor particulate matter and black carbon and autonomic function differ between patients with chronic obstructive pulmonary disease and their healthy spouses. Environ Pollut 236:40–48. https://doi.org/10.1016/j.envpol.2018.01.064 CrossRefPubMed

38.

Middlekauff HR, Park J, Moheimani RS (2014) Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: mechanisms and implications for cardiovascular risk. J Am Coll Cardiol 64(16):1740–1750. https://doi.org/10.1016/j.jacc.2014.06.1201 CrossRefPubMed

39.

Lombardo TW, Epstein LH (1986) The nicotine paradox: effect of smoking on autonomic discrimination. Addict Behav 11(3):341–344CrossRefPubMed

40.

Wang X, Jiang Z, Chen B, Zhou L, Kong Z, Zuo S, Liu H, Yin S (2016) Cardiac autonomic function in patients with acute exacerbation of chronic obstructive pulmonary disease with and without ventricular tachycardia. BMC Pulm Med 16(1):124. https://doi.org/10.1186/s12890-016-0287-0 CrossRefPubMedPubMedCentral

41.

Andreas S, Haarmann H, Klarner S, Hasenfuss G, Raupach T (2014) Increased sympathetic nerve activity in COPD is associated with morbidity and mortality. Lung 192(2):235–241. https://doi.org/10.1007/s00408-013-9544-7 CrossRefPubMed

42.

Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, Magnussen H (2010) Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 138(1):32–38. https://doi.org/10.1378/chest.09-2810 CrossRefPubMed

43.

Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D, Hueper K, Parikh MA, Gomes AS, Michos ED, Lima JAC, Barr RG (2013) Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The multi-ethnic study of atherosclerosis COPD study. Chest 144(4):1143–1151. https://doi.org/10.1378/chest.13-0183 CrossRefPubMedPubMedCentral

44.

Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Sohler S, Vogelmeier C, Ficker JH, Muckter H, Jorres RA, Consortium C (2016) Systematic analysis of self-reported comorbidities in large cohort studies—a novel stepwise approach by evaluation of medication. PLoS One 11(10):e0163408. https://doi.org/10.1371/journal.pone.0163408 CrossRefPubMedPubMedCentral

45.

Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO (2018) Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. Clin Res Cardiol 107(2):138–147. https://doi.org/10.1007/s00392-017-1165-3 CrossRefPubMed

Title: Time-updated resting heart rate predicts mortality in patients with COPD
Authors: Albert J. Omlor
Franziska C. Trudzinski
Mohamad Alqudrah
Frederik Seiler
Frank Biertz
Claus F. Vogelmeier
Tobias Welte
Henrik Watz
Benjamin Waschki
Titus J. Brinker
Stefan Andreas
Sebastian Fähndrich
Peter Alter
Rudolf A. Jörres
Michael Böhm
Robert Bals
German COSYCONET Cohort
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keyword: Chronic Obstructive Lung Disease
Published in: Clinical Research in Cardiology / Issue 6/2020
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01572-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Time-updated resting heart rate predicts mortality in patients with COPD

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Correction to: The potential prognostic utility of salivary galectin-3 concentrations in heart failure

A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis

Outcome differences and device performance of the subcutaneous ICD in patients with and without structural heart disease

Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure

Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials

Correlation of machine learning computed tomography-based fractional flow reserve with instantaneous wave free ratio to detect hemodynamically significant coronary stenosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page